MCMedicalCodingSoftware
Free trial
XW013S9

XW013S9 — Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9

Billable / specific codeICD-10-PCS

CMS abbreviated title: Introduce Epcoritamab Moncln Ab in Subcu, Perc, New Tech 9

How XW013S9 is built

Every ICD-10-PCS code is seven independent character positions. Each one is a separate decision, and the meaning of a character depends on the positions before it.

  1. XSectionNew Technology — What family of procedure this is
  2. WBody systemWhich system it acts on
  3. 0Root operationThe objective — the verb of the procedure
  4. 1Body partThe specific site
  5. 3ApproachHow the site was reached
  6. SDeviceWhat was left in place, if anything
  7. 9QualifierA further distinction where one applies

Codes near XW013S9

In CMS’s own ordering, which groups codes that differ by only the last character or two — usually the approach, device or qualifier.

  • XW0136AIntroduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10
  • XW01397Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
  • XW013F5Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
  • XW013G6Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW013H6Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW013K6Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW013L9Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
  • XW013S6Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW013S9Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
  • XW013T6Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW013TBIntroduction of Rozanolixizumab-noli Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 11
  • XW013U6Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW013V7Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
  • XW013W5Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
  • XW013W7Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
  • XW01X27Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7
  • XW020D8Introduction of Engineered Allogeneic Thymus Tissue into Muscle, Open Approach, New Technology Group 8
ICD-10-PCSFY2026